Brilacidin: Phase IIb ongoing

Cellceutix said an independent DSMB recommended the continuation of a double-blind, U.S. Phase IIb trial of IV brilacidin based on an interim safety analysis after about 50% of

Read the full 285 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE